Limited-stage MCL: a low-risk disease in need of more intensive treatment?

  • Jo JC & al.
  • Ann Hematol
  • 18 Dec 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In a review of clinical characteristics and treatment outcomes in patients with limited-stage mantle cell lymphoma (MCL), patients demonstrated low-risk prognostic scores and clinical characteristics, but eventual relapse was common.

Why this matters

  • Although 15% of patients with MCL present with localized (Ann Arbor Stage I or II) disease, little is known regarding optimal clinical features and treatment outcomes.

Study design

  • Analysis of clinical features and treatment outcomes in 41 patients with limited-stage MCL diagnosed in the years 2000-2016.
  • Patient data were sourced from 16 institutions of the Consortium for Improving Survival of Lymphoma group.
  • Median patient age at diagnosis: 66 (range, 19-85) years.
  • Funding: None disclosed.

Key results

  • Clinical characteristics:
    • 68.3% of patients had low-risk disease per the MCL International Prognostic Index.
    • 29.3% of patients were asymptomatic.
  • Treatment:
    • 90.1% of patients received chemotherapy as first treatment.
  • Treatment outcomes:
    • 97.4% objective response rate.
    • 78.0% complete response; 9.8% partial response.
    • With 40.6 months median follow-up: 59.1% relapse-free survival (RFS) at 42 months; median OS was not reached.
    • 37.6% estimated 5-year RFS; 80.4% estimated 5-year OS.

Limitations

  • Retrospective data.